Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2223334 | 0.90 | CYP1A2 (0.38) | CYP1A2CYP2C19CYSLTR1GPBAR1ALDH1A1 | |
| SCHEMBL14925219 | 0.81 | PDE10A (0.40) | GRM1CYP1A2CYP2C19CYSLTR1GPBAR1 | |
| SCHEMBL5466370 | 0.78 | BACE1 (0.47) | CYP2C19CYSLTR1ALDH1A1CYSLTR2 | |
| SCHEMBL3951224 | 0.77 | GPBAR1 (0.55) | CYP1A2CYP2C19CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL14925246 | 0.77 | PDE10A (0.37) | GRM1CYP1A2CYP2C19CYSLTR1GPBAR1 | |
| SCHEMBL12517339 | 0.77 | PDE10A (0.41) | CYP1A2CYP2C19CYSLTR1GPBAR1ALDH1A1 | |
| SCHEMBL2672157 | 0.75 | TERT (0.50) | CYP1A2CYP2C19PDE10AALOX5 | |
| SCHEMBL14930078 | 0.75 | CYP3A4 (0.40) | CYSLTR1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL2272626 | 0.75 | CCR1 (0.45) | GRM1CYSLTR1GPBAR1PDE10A | |
| SCHEMBL14925257 | 0.72 | PDE10A (0.38) | CYP1A2CYP2C19CYSLTR1GPBAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993767-B2 | Multiphoton activable quinoline derivatives, their preparation and their uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-03-31 | — | — | US | disclosed |
| EP-2523937-B1 | Multiphoton activable quinoline derivatives, their preparation and their uses | CENTRE NAT RECH SCIENT (FR) | 2015-03-11 | — | — | EP | disclosed |
| US-20130116281-A1 | Multiphoton Activable Quinoline Derivatives, Their Preparation and Their Uses | UNIVERSITÉ PARIS CITÉ (FR) | 2013-05-09 | — | — | US | disclosed |
| EP-2523937-A1 | MULTIPHOTON ACTIVABLE QUINOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USES | Centre National De La Recherche Scientifique (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086469-A1 | MULTIPHOTON ACTIVABLE QUINOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116281-A1 | Multiphoton Activable Quinoline Derivatives, Their Preparation and Their Uses | NQO2, ACHE, NQO1 | GRM1 2788/4885CYP1A2 43/4885CYP2C19 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.